WO2001037874A3 - Treatment of psoriasis by using an antibody to tnf alpha - Google Patents
Treatment of psoriasis by using an antibody to tnf alpha Download PDFInfo
- Publication number
- WO2001037874A3 WO2001037874A3 PCT/US2000/042161 US0042161W WO0137874A3 WO 2001037874 A3 WO2001037874 A3 WO 2001037874A3 US 0042161 W US0042161 W US 0042161W WO 0137874 A3 WO0137874 A3 WO 0137874A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- psoriasis
- treatment
- antibody
- tnf alpha
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU30824/01A AU3082401A (en) | 1999-11-24 | 2000-11-15 | Therapy of psoriasis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16747099P | 1999-11-24 | 1999-11-24 | |
US60/167,470 | 1999-11-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001037874A2 WO2001037874A2 (en) | 2001-05-31 |
WO2001037874A3 true WO2001037874A3 (en) | 2002-01-10 |
Family
ID=22607484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/042161 WO2001037874A2 (en) | 1999-11-24 | 2000-11-15 | Treatment of psoriasis by using an antibody to tnf alpha |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3082401A (en) |
WO (1) | WO2001037874A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8906373B2 (en) | 2002-07-19 | 2014-12-09 | Abbvie Biotechnology Ltd. | Use of TNF-alpha inhibitor for treatment of psoriasis |
US8961973B2 (en) | 2004-04-09 | 2015-02-24 | Abbvie Biotechnology Ltd. | Multiple-variable dose regimen for treating TNFα-related disorders |
US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20030206898A1 (en) * | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
CN102764436A (en) * | 2002-07-19 | 2012-11-07 | 艾博特生物技术有限公司 | Treatment of TNF alpha related disorders |
US10080779B2 (en) | 2004-12-15 | 2018-09-25 | Universite D'angers | Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM |
EP1671642A1 (en) * | 2004-12-15 | 2006-06-21 | Universite D'angers | Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof. |
EP2666472A3 (en) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
JP2023554200A (en) | 2020-12-09 | 2023-12-26 | エイチケー イノ.エヌ コーポレーション | Anti-OX40L antibody, anti-OX40L and anti-TNFα bispecific antibody, and their uses |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992001472A1 (en) * | 1990-07-19 | 1992-02-06 | Celltech Limited | Multivalent anti-cytokine immunoglobulins |
-
2000
- 2000-11-15 AU AU30824/01A patent/AU3082401A/en not_active Abandoned
- 2000-11-15 WO PCT/US2000/042161 patent/WO2001037874A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992001472A1 (en) * | 1990-07-19 | 1992-02-06 | Celltech Limited | Multivalent anti-cytokine immunoglobulins |
Non-Patent Citations (8)
Title |
---|
C. ANTONI ET AL.: "Successful treatment of psoriatic arthritis with infliximab in a MRI controlled study", JOURNAL OF RHEUMATOLOGY, vol. 27, no. suppl. 59, August 2000 (2000-08-01), Toronto, Canada, pages 24, XP000990586 * |
C. ANTONI ET AL.: "Successful treatment of severe psoriatic arthritis with infliximab.", ARTHRITIS & RHEUMATISM, vol. 42, September 1999 (1999-09-01), New York, NY, USA, pages S371, XP002165648 * |
C. BONIFATI ET AL.: "Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity.", CLINICAL AND EXPERIMENTAL DERMATOLOGY, vol. 19, no. 5, September 1994 (1994-09-01), Oxford, GB, pages 383 - 387, XP000990570 * |
C. OH ET AL.: "Treatment with anti-tumor necrosis factor alpha (TNF alpha) monoclonal antibody dramatically decreases the clinical activity of psoriatis lesions.", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 42, no. 5 part 1, May 2000 (2000-05-01), St. Louis, MO, USA, pages 829 - 830, XP000990581 * |
F. BAERT ET AL.: "Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis", GASTROENTEROLOGY, vol. 116, no. 1, January 1999 (1999-01-01), New York, NY, USA, pages 22 - 28, XP002165649 * |
K. MACE ET AL.: "Pharmacodynamics of cA2: implications for immunotherapy.", EUROPEAN CYTOKINE NETWORK, vol. 7, no. 2, April 1996 (1996-04-01), Montrouge, pages 308, XP000990601 * |
M. FELDMANN ET AL.: "TNFalpha is an effective therapeutic target for rheumatoid arthritis.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 766, 1995, New York, NY, USA, pages 272 - 278, XP000990602 * |
P. ETTEHADI ET AL.: "Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 96, no. 1, April 1994 (1994-04-01), Oxford, GB, pages 146 - 151, XP000990589 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8906373B2 (en) | 2002-07-19 | 2014-12-09 | Abbvie Biotechnology Ltd. | Use of TNF-alpha inhibitor for treatment of psoriasis |
US8961973B2 (en) | 2004-04-09 | 2015-02-24 | Abbvie Biotechnology Ltd. | Multiple-variable dose regimen for treating TNFα-related disorders |
US8961974B2 (en) | 2004-04-09 | 2015-02-24 | Abbvie Biotechnology Ltd. | Multiple-variable dose regimen for treating TNFα-related disorders |
US8986693B1 (en) | 2004-04-09 | 2015-03-24 | Abbvie Biotechnology Ltd. | Use of TNFα inhibitor for treatment of psoriasis |
US9187559B2 (en) | 2004-04-09 | 2015-11-17 | Abbvie Biotechnology Ltd | Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease |
US9499615B2 (en) | 2004-04-09 | 2016-11-22 | Abbvie Biotechnology Ltd | Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease |
US9512216B2 (en) | 2004-04-09 | 2016-12-06 | Abbvie Biotechnology Ltd. | Use of TNFα inhibitor |
US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
US9284370B1 (en) | 2007-06-11 | 2016-03-15 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
Also Published As
Publication number | Publication date |
---|---|
WO2001037874A2 (en) | 2001-05-31 |
AU3082401A (en) | 2001-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1600042I1 (en) | Therapeutic use of anti-CS1 antibodies | |
AU1520195A (en) | Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels | |
WO1997017446A3 (en) | HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF | |
WO2002074337A8 (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
BG107537A (en) | Method for the inhibition of human tnf alpha activity and its application | |
UA111707C2 (en) | APPLICATION OF SELECTED HUMAN ANTIBODY ANTI-TNF-ALPHA | |
IT9068053A0 (en) | PREPARATION INCLUDING BIOTINYLATED MONOCLONAL ANTIBODIES, AVIDIN AND BIOTIN, FOR THE DIAGNOSIS AND THERAPY OF CANCER DISEASES AND ITS USE | |
AU2003248245A1 (en) | Remedies for diseases caused by vascular contraction or dilation | |
ZA200508389B (en) | Humanized antibodies to interferon alpha receptor-1(IFNAR-1) | |
WO2001037874A3 (en) | Treatment of psoriasis by using an antibody to tnf alpha | |
DE60045240D1 (en) | ANTIBODIES TO TNF ALPHA FOR THE THERAPY OF STEROID-RESISTANT ASTHMA | |
WO2001051044A3 (en) | Substances for use in treating psoriasis | |
ITTO940748A0 (en) | PROSTHETIC CONDUIT PARTICULARLY FOR THE TREATMENT OF CARDIOVASCULAR DISEASES. | |
WO2003097082A3 (en) | Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies | |
AU2003303217A1 (en) | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | |
EE9900010A (en) | Therapeutic applications of T-BAM (CD40L) technology for the treatment of smooth muscle cell related diseases | |
WO1996040041A3 (en) | Antibodies to fas antigen capable of inhibiting apoptosis | |
IT1233005B (en) | MONOCLONAL HUMAN ANTIBODY, THERAPEUTIC COMPOSITION THAT CONTAINS IT MOBILE LINE ABLE TO PRODUCE THE ANTIBODY, PROCEDURE FOR ITS PRODUCTION | |
AU2001280256A1 (en) | Methods for the diagnosis and/or treatment of diseases related to anti-phospholipid antibodies and devices used therein | |
WO2002000822A3 (en) | A NOVEL POLYPEPTIDE, A HUMAIN PROTEIN SYNTHESIS INITIATION FACTOR SUB-UNIT 2 β 16.5 AND THE POLYNUCLEOTIDE ENCODING THE POLYPEPTIDE | |
AU2003295504A1 (en) | Development of therapeutics for the treatment of endotoxin-mediated diseases | |
IT8821369A0 (en) | PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASES. | |
ITRM920516A0 (en) | COMPOSITION AND ITS USE FOR THE THERAPEUTIC TREATMENT OF DERMATIC DISEASES, PARTICULARLY PSORIASIS. | |
WO2002008421A1 (en) | A novel polypeptide, a human tumor necrosis factor receptor 21.45 and the polynucleotide encoding the polypeptide | |
WO2001075010A3 (en) | A novel polypeptide, human nuclear transduction protein 25 containing a structural atp/gtp domain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |